TMDX vs. MASI, ITGR, LIVN, CNMD, INMD, SLNO, BLFS, ZYXI, AXGN, and EDAP
Should you be buying TransMedics Group stock or one of its competitors? The main competitors of TransMedics Group include Masimo (MASI), Integer (ITGR), LivaNova (LIVN), CONMED (CNMD), InMode (INMD), Soleno Therapeutics (SLNO), BioLife Solutions (BLFS), Zynex (ZYXI), AxoGen (AXGN), and Edap Tms (EDAP). These companies are all part of the "electromedical equipment" industry.
TransMedics Group (NASDAQ:TMDX) and Masimo (NASDAQ:MASI) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.
Masimo received 366 more outperform votes than TransMedics Group when rated by MarketBeat users. Likewise, 63.84% of users gave Masimo an outperform vote while only 54.78% of users gave TransMedics Group an outperform vote.
99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 86.0% of Masimo shares are owned by institutional investors. 7.0% of TransMedics Group shares are owned by insiders. Comparatively, 9.7% of Masimo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Masimo has a net margin of 4.01% compared to TransMedics Group's net margin of -3.43%. Masimo's return on equity of 13.26% beat TransMedics Group's return on equity.
TransMedics Group has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Comparatively, Masimo has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.
In the previous week, Masimo had 12 more articles in the media than TransMedics Group. MarketBeat recorded 21 mentions for Masimo and 9 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.53 beat Masimo's score of 0.26 indicating that TransMedics Group is being referred to more favorably in the media.
Masimo has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.
TransMedics Group presently has a consensus price target of $119.00, suggesting a potential downside of 12.76%. Masimo has a consensus price target of $138.71, suggesting a potential upside of 11.42%. Given Masimo's higher possible upside, analysts plainly believe Masimo is more favorable than TransMedics Group.
Summary
Masimo beats TransMedics Group on 12 of the 18 factors compared between the two stocks.
Get TransMedics Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
TransMedics Group Competitors List
Related Companies and Tools